William S. Chen

University of California, San Francisco — United States

Medicine · Health Sciences

23h-index5.2kcitations96works1.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Treatment and Research(55), Immunotherapy and Immune Responses(21), Cancer Immunotherapy and Biomarkers(20), Cancer Genomics and Diagnostics(15), Cancer, Lipids, and Metabolism(14)

Publications96 total

Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer
Nature Genetics·2025· 1 citedOpen Access
Utility of metastasis-directed radiotherapy with and without hormonal therapy in management of oligometastatic prostate cancer
JNCI Cancer Spectrum·2025Open Access
Genome-wide CRISPR screens identify PTGES3 as a novel AR modulator
2025Open Access
Characterizing transportation need and missed visits among patients receiving radiotherapy.
Journal of Clinical Oncology·2025
Patient transit and radiotherapy: Cost-effectiveness approach to environmental health savings.
Journal of Clinical Oncology·2025
Racial variation in the advanced prostate cancer genome
Prostate Cancer and Prostatic Diseases·2025· 1 citedOpen Access
Supplementary Figure 5 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
2025Open Access
Supplementary Figure 3 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
2025Open Access
Supplementary Figure 7 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
2025Open Access
Supplementary Figure 1 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
2025Open Access
Supplementary Tables 1-7 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
2025Open Access
Supplementary Figure 4 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
2025Open Access
Supplementary Figure 2 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
2025Open Access
Supplementary Figure 6 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
2025Open Access
Supplementary Figure 3 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
2025Open Access
Supplementary Figure 2 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
2025Open Access
Supplementary Figure 5 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
2025Open Access
Supplementary Tables 1-7 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
2025Open Access
Supplementary Figure 4 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
2025Open Access
Supplementary Figure 1 from Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer
2025Open Access
page 1 of 5Next →

Frequent Co-authors

David A. Quigley(27), Felix Y. Feng(27), Eric J. Small(25), Shuang G. Zhao(17), Adam Foye(17), Rahul Aggarwal(15), Martin Sjöström(14), Joshi J. Alumkal(14), Tomasz M. Beer(13), Martin Gleave(13), Matthew B. Rettig(13), Jonathan Chou(11), Robert E. Reiter(11), Primo N. Lara(10), Elai Davicioni(10), Raunak Shrestha(10), Mohammed Alshalalfa(9), Lisa N. Chesner(9), Christopher P. Evans(9), Luke A. Gilbert(9)